Cargando…

Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C

BACKGROUND: The Netherlands has a low hepatitis C virus (HCV) prevalence, estimated at 0.16%. Previous studies have shown that up to 30% of the diagnosed HCV population in the Netherlands has been lost to follow-up (LTFU). Retrieval of these patients could halt progression of liver disease in infect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isfordink, Cas J, Brakenhoff, Sylvia M, van Dijk, Marleen, van der Valk, Marc, de Knegt, Rob J, Arends, Joop E, Drenth, Joost PH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199651/ https://www.ncbi.nlm.nih.gov/pubmed/32377367 http://dx.doi.org/10.1136/bmjgast-2020-000396

Ejemplares similares

Legal and Ethical Challenges in Developing a Dutch Nationwide Hepatitis C Retrieval Project (CELINE)
por: van Dijk, Marleen, et al.
Publicado: (2020)

The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030
por: van Dijk, Marleen, et al.
Publicado: (2021)

Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
por: Zaimi, Yosra, et al.
Publicado: (2021)

Loss to follow‐up in the hepatitis C care cascade: A substantial problem but opportunity for micro‐elimination
por: van Dijk, Marleen, et al.
Publicado: (2020)

Liver‐related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders
por: Isfordink, Cas J., et al.
Publicado: (2022)

Erratum to: Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Effect of season and sunlight on viral kinetics during hepatitis C virus therapy
por: Hernández-Alvarez, Noemi, et al.
Publicado: (2017)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study
por: Volpato, Sofia, et al.
Publicado: (2017)

Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations
por: Gilman, Andrew J, et al.
Publicado: (2018)

Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus
por: Carpentier, Arnaud, et al.
Publicado: (2020)

Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C
por: Hallsworth, Kate, et al.
Publicado: (2021)

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus
por: Llibre, Alba, et al.
Publicado: (2018)

Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C
por: McPherson, Stuart, et al.
Publicado: (2020)

Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection
por: Deuffic-Burban, S, et al.
Publicado: (2008)

Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection
por: Fitzmaurice, Karen, et al.
Publicado: (2011)

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
por: Xiao, Fei, et al.
Publicado: (2015)

Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection
por: Rao, Huiying, et al.
Publicado: (2014)

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience
por: Nguyen, Peter, et al.
Publicado: (2017)

Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score
por: Bhatti, Hamza Waqar, et al.
Publicado: (2019)

The use of generic medications for hepatitis C
por: Freeman, James A. D., et al.
Publicado: (2016)

Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men
por: Thomson, Emma C, et al.
Publicado: (2010)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model
por: Levander, Sepideh, et al.
Publicado: (2018)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies
por: Bankwitz, Dorothea, et al.
Publicado: (2021)

Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes
por: Mengshol, J A, et al.
Publicado: (2009)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China
por: Zhang, H W, et al.
Publicado: (2008)

Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis
por: Saeki, Chisato, et al.
Publicado: (2022)

Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience
por: Pape, Simon, et al.
Publicado: (2020)

Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection
por: Jin, Young-Joo, et al.
Publicado: (2014)

COVID-19 and liver cancer: lost patients and larger tumours
por: Geh, Daniel, et al.
Publicado: (2022)

The paradox of NKp46(+) natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment
por: Pembroke, Tom, et al.
Publicado: (2014)

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
por: Watanabe, Tsunamasa, et al.
Publicado: (2013)

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis
por: Yee, Brittany E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c0aalatnui4s35h4oqrdgg6t8s